Tetravalent dengue vaccine: Additional Phase III data

Additional data from a double-blind, Asian Phase III trial in 10,275 healthy children ages 2-14 showed that 0.5 mL subcutaneous injections of Sanofi’s tetravalent dengue vaccine given at 0, 6 and 12 m...